Consortium Member of the Month

Our consortium member of the month for the month of February goes to Kathryn Johnson from Mount Sinai Health System!

Kathryn B. Johnson, DNP, MSc, FNP-BC

We are proud to highlight Kathryn Johnson as the MPN-RC Member of the Month. For more than six years, Kathryn has been an integral member of the research program and we are incredibly fortunate to have her as part of the team. Her dedication to providing high-level patient care and to supporting patients throughout their clinical trial journeys is unmatched. She brings a patient-centered perspective to the design of MPN-RC protocols, ensuring they are practical and inclusive. In her role as Advanced Practice Provider Manager for the Liquid Tumor Clinical Research Programs at Mount Sinai, her work continues to make a lasting impact in the MPN space and beyond.

Nominated by: Dr. John Mascarenhas

Kathryn, thank you so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

We are HIRING!

Mount Sinai Health System is looking to hire two Senior Scientists. Use the links below for more information and to apply for the position(s).

Apply HERE!

Apply HERE!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract